Annexon, Inc.
ANNXNasdaq
$5.80
↓ -1.5%Jul 17 close · end-of-day
Price
1Y↑ +141.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.1B
Enterprise Value
$901.3M
P/E
—
P/S
—
P/B
5.5
EV/EBITDA
—
PEG
—
FCF Yield
-16.3%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$196.5M
Free Cash Flow (TTM)
-$183.2M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-96.1%
ROIC
—
Debt / Equity
—
Net Cash
$225.0M
Return 1Y
+147.9%
Company profile
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain-baré syndrome. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- CEO
- Douglas Love
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 60
- Headquarters
- California
- Website
- annexonbio.com
Management & directors
- Yednock TedEVP & CHIEF INNOVATION OFFICER
- Artis Dean RichardEVP & CHIEF SCIENTIFIC OFFICER
- Dananberg JamieCHIEF MEDICAL OFFICER
- Lew JenniferEVP & CHIEF FINANCIAL OFFICER
- Overdorf MichaelEVP & CHIEF BUSINESS OFFICER
Roles derived from SEC Form 4 filings.
Earnings
ANNX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.23↓ -37.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$63.5M | -$130.7M | -$145.6M | -$143.7M | -$154.1M | -$216.4M |
| Net income | -$63.4M | -$130.3M | -$141.9M | -$134.2M | -$138.2M | -$206.7M |
| Diluted EPS | — | -$3.40 | -$2.60 | -$1.77 | -$1.01 | -$1.34 |
| Operating cash flow | -$53.1M | -$106.1M | -$116.3M | -$121.1M | -$118.0M | -$186.4M |
| Free cash flow | -$53.6M | -$107.8M | -$122.8M | -$121.3M | -$118.0M | -$186.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$33.6M | -$39.4M | -$52.5M | -$57.4M | -$51.7M | -$57.0M | -$50.3M | -$46.1M |
| Net income | -$29.6M | -$34.8M | -$48.6M | -$54.4M | -$49.2M | -$54.9M | -$48.3M | -$44.1M |
| Diluted EPS | -$0.23 | -$0.25 | -$0.32 | -$0.37 | -$0.34 | -$0.37 | -$0.26 | -$0.23 |
| Operating cash flow | -$21.7M | -$32.0M | -$36.0M | -$50.1M | -$38.1M | -$52.3M | -$45.9M | -$46.8M |
| Free cash flow | — | — | — | -$50.1M | -$38.1M | -$52.4M | -$45.9M | -$46.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 16, 2026
Jun 9, 2026
Jun 4, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Yednock Ted· EVP & CHIEF INNOVATION OFFICER | Option exercise | 30,646 | $1.85 | $56,698.16 | filing |
| 2026-05-28 | Satter Muneer A | Buy | 613,497 | $5.41 | $3.3M | filing |
| 2026-05-11 | Carson William H. | Buy | 8,000 | $5.78 | $46,240.00 | filing |
| 2026-04-10 | Carson William H. | Buy | 8,000 | $6.20 | $49,600.00 | filing |
| 2026-03-10 | Carson William H. | Buy | 8,000 | $5.67 | $45,360.00 | filing |
| 2026-03-02 | ARTIS DEAN RICHARD· EVP & CHIEF SCIENTIFIC OFFICER | Sale | 5,894 | $5.43 | $32,004.42 | filing |
| 2026-03-02 | Dananberg Jamie· CHIEF MEDICAL OFFICER | Sale | 5,820 | $5.43 | $31,602.60 | filing |
| 2026-03-02 | Yednock Ted· EVP & CHIEF INNOVATION OFFICER | Sale | 5,566 | $5.42 | $30,167.72 | filing |
| 2026-03-02 | Lew Jennifer· EVP & CHIEF FINANCIAL OFFICER | Sale | 5,565 | $5.42 | $30,162.30 | filing |
| 2026-03-02 | Overdorf Michael· EVP & CHIEF BUSINESS OFFICER | Sale | 4,339 | $5.42 | $23,517.38 | filing |
| 2026-02-19 | Yednock Ted· EVP & CHIEF INNOVATION OFFICER | Award | 62,500 | $0.00 | $0.00 | filing |
| 2026-02-19 | Dananberg Jamie· CHIEF MEDICAL OFFICER | Award | 56,250 | $0.00 | $0.00 | filing |
| 2026-02-19 | Overdorf Michael· EVP & CHIEF BUSINESS OFFICER | Award | 62,500 | $0.00 | $0.00 | filing |
| 2026-02-19 | ARTIS DEAN RICHARD· EVP & CHIEF SCIENTIFIC OFFICER | Award | 62,500 | $0.00 | $0.00 | filing |
| 2026-02-19 | Lew Jennifer· EVP & CHIEF FINANCIAL OFFICER | Award | 62,500 | $0.00 | $0.00 | filing |
| 2026-02-18 | Yednock Ted· EVP & CHIEF INNOVATION OFFICER | Sale | 7,857 | $5.11 | $40,149.27 | filing |
| 2026-02-18 | Lew Jennifer· EVP & CHIEF FINANCIAL OFFICER | Sale | 7,851 | $5.11 | $40,118.61 | filing |
| 2026-02-18 | Overdorf Michael· EVP & CHIEF BUSINESS OFFICER | Sale | 6,225 | $5.10 | $31,747.50 | filing |
| 2026-02-18 | Dananberg Jamie· CHIEF MEDICAL OFFICER | Sale | 5,290 | $5.10 | $26,979.00 | filing |
| 2026-02-18 | ARTIS DEAN RICHARD· EVP & CHIEF SCIENTIFIC OFFICER | Sale | 5,290 | $5.10 | $26,979.00 | filing |
| 2025-12-30 | Carson William H. | Buy | 4,115 | $5.02 | $20,657.30 | filing |
| 2025-12-01 | Choi Jung | Buy | 33,000 | $4.19 | $138,270.00 | filing |
| 2025-12-01 | Carson William H. | Buy | 4,115 | $4.47 | $18,394.05 | filing |
| 2025-11-21 | Satter Muneer A | Buy | 422,613 | $4.28 | $1.8M | filing |
| 2025-11-20 | Satter Muneer A | Buy | 400,000 | $4.48 | $1.8M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.